Markers of cell damage of buffy-coat derived platelet concentrates in additive solutions
Authors:
L. Řehořová 1,2; R. Procházková 1,2
Authors‘ workplace:
Transfuzní oddělení, Krajská nemocnice Liberec, a. s.
1; Ústav zdravotnických studií, Technická univerzita v Liberci
2
Published in:
Transfuze Hematol. dnes,17, 2011, No. 2, p. 85-91.
Category:
Comprehensive Reports, Original Papers, Case Reports
Overview
Background:
The aim of the study was to compare markers of cell damage and platelet activation of buffy-coat derived platelet concentrates (PCs) during storage in two types of additive solutions (PASs) in two different storage bags. PASs reduce plasma-associated transfusion reactions and conserve plasma for transfusion or fractionation.
Materials and Methods:
PCs were prepared from leukocyte-depleted pools of four buffy-coats (BCPs) suspended in one of 70% PASs: 30% plasma (Composol, Fresenius - Kabi; T-Sol, Baxter Corp.). Two different storage bags were used (R4R7036, Fenwal; Autostop, Pall Corp.). On the days 0 and 5 of storage samples were tested for PLT concentration, pH, glucose, lactate and sP-Selectin. Data were analyzed by analysis with two-sample t-tests, paired test and Pearson correlation coefficient. Statistical significance was assessed at p <0.05.
Results:
PLT yields were higher then 2x1011platelets/unit in all of PCs. There was the significant decrease of platelet concentration during storage for 5 days in all bags or media. The pH of all PCs was 6.8 on the 5th day of storage. Glucose consumption and lactate production in all types of bags and media were significantly different during storage. Lactate production and glucose consumption in T-Sol were higher than those items in Composol and they resulted in lower pH values. We showed the influence of storage bags for platelet activation, too.
Conclusion:
The development of markers of cell damage in PCs was influenced mainly by used platelet storage solution, platelet storage bags affected the status of platelet activation.
Key words:
platelet additive solution, platelet, platelet function, platelet activation, platelet storage
Sources
1. Zhang JG, Carter JC, Culibrk B, et al. Buffy coat platelet variables and meatabolism during storage in additive solutions or plasma. Transfusion 2008; 48: 847-856.
2. Gullikson H, AuBuchon JP, Vesterinen M, et al. Storage of platelets in additive solutions: a pilot in vitro study of the effects of potassium and magnesium. Vox Sanq 2002; 82: 131–136.
3. Diedrich B, Sandgren P, Jansson B, et al. In vitro and in vivo effects of potassium and magnesium on storage up to 7 days of apheresis platelet concentrates in platelet additive solutions. Vox Sanq 2008; 94: 96-102.
4. Cardigan R, Sutherland J, Garwood M, et al. In vitro function of buffy coat – derived platelet concentrates stored for 9 days in CompoSol, PAS II or 100% plasma in three different storage bags. Vox Sanq 2008; 94: 103-112.
5. Murphy S. Platelelets from pooled buffy coats: an update. Transfusion 2005; 45: 634 – 639.
6. Azuma H, Hirayama J, Akino M, et. al. Reduction in adverse reactions to platelets by removal of plasma supernatant and resuspension in a new additive solution (M-sol). Transfusion 2009; 49: 214-218.
7. Vetlesen A, Mirlashari MR, Torshein IA, Kjeldsen – Kragh J. Plaletet activation and residual activation potential during storage of hyperconcentrated platelet products in two different platelet additive solutions. Transfusion 2005; 45: 1349-1355.
8. Van der Meer PF, Kerkhofs JL, Curvers J, et al. In vitro comparison of platelet storage in plasma and in four platelet additive solutions, and the effect of pathogen reduction: a proposal for an in vitro rating system. Vox Sanq 2010; 98: 517-524.
9. Sweeney J, Kouthab N, Holme S, Kurtis J, Cheves T, Nelson E. Storage of platelet rich plasma-derived platelet concentrate pools in plasma and additive solution. Transfusion 2006; 46: 835-840.
10. Hornsey VS, McColl K, Drummond O, et al. Extended storage of platelets in SSP+ platelet additive solution. Vox Sanq 2006; 91:41-46.
11. Seghatchian J, Krailadsiri P. The Platelet storage lession. Transf Med Rev 1997; 11: 130-144.
12. Solheim BG, Flesland O, Seghatchian J, et al. Clinical implications of red blood cell and platelet storage lessions: an overview. Transfus Apher Sci 2004; 31(3): 185-189.
13. Vetlesen A, Mirlashari MR, Ezligini F, Kjeldsen – Kragh J. Evaluation of platelets activation and cytokine release during storage of platelet concentrates processed from buffy coats either manually or by the automated OrbiSac system. Transfusion 2007; 47: 126-132.
14. Curvers J, van Pampus ECM, Feijge MAH, et al. Decreased responsiveness and development of activation markers of PLTs stored in plasma. Transfusion 2004; 44, 49-58.
15. Perrotta PL, Perrotta ChL, Snyder EL. Apoptotic activity in stored human platelets. Transfusion 2003; 43: 526-535.
16. Krailadsiri P, Seghatchian J, Zmíral J, Vissac A, Contreras M. Annexin V, a new marker of platelet storage lession: correlaton with dMPV. Transfus Sci 1997; 18 (2): 223-226.
17. Ringwald J, Haager B, Krex D, et al. Impact of different hold time before addition of platelet additive solution on the vitro quality of apheresis platelets. Transfusion 2006; 46: 942-948.
18. van der Meer PF, Liefting LAE, Pietersz RNI. The effect of interruption of agitation on the in vitro measures of platelet concentrates in additive solutions. Transfusion 2007; 47: 955-959.
19. Krailadsiri P, Seghatchian J. Are all platelet concentrates equivalent? Vox Sanq 2000; 78: 171-175.
20. Procházková R, Andrýs C, Hubáčková L Krejsek J. Markers of apoptosis and platelet activation in platelet concentrates collected by apheresis. Transfus Apher Sci 2007; 37: 115-123.
21. Sweeney J, Kouttab N, Holme S, Kurtis J, Cheves T, Nelson E. Storage of platelet-rich plasma-derived platelet concentrate pools in plasma and additive solutions. Transfusion 2006; 46: 835-840.
22. Krailadsiri P, Seghatchian J, Williamson LM. Platelet storage lession of WBC-reduced, pooled buffy coat –derived platelet concentrates prepared in three in-process filter/storage bag combinations. Transfusion 2001; 41: 243-250.
23. Dijkstra-Tiekstra MJ, Pietersz RNI, Huijgens PC. Correlation between the extent of platelet activation in platelet concentrates and in vitro and in vivo parameters. Vox Sanquinis 2004; 87: 257-263.
24. Holme S, Sweeney JD, Sawyer S, Elfath MD. The expression of P-selectin during collection, processing, and storage of platelet concentrates: Relationship to loss in vivo viability. Transfusion 1997; 37(1): 12-17.
25. Vyhl. 143/2008 Sb. o stanovení bližších požadavků o zajištění jakosti a bezpečnosti lidské krve a jejích složek (vyhláška o lidské krvi).
26. Gutensohn K, Alisch A, Geidel K, Crespeigne N, Kuehnl P. Annexin V and platelet antigen expression is not altered during storage of platelet concentrates obtained with AMICUS cell separator. Transf Sci 1999; 20: 113-119.
27. Lai M, Rumi C, D Onofrio G, et al. Phosphatidylserine exposure in platelet concentrates during the storage period: differences between the platelets collected with different cell separators. Transfus Apher Sci 2002; 27: 239-245.
28. Gutensohn K, Geidel K, Kroeger N, et al. Platelet function testing in apheresis products: flow cytometric, resonance thrombographic /RTG) and rotational thrombelastographic (roTEG) analyses. Transfusion Apher Sci 2002; 26: 147-155.
29. Cardigan R, Turner C, Harrison P. Current methods of assessing platelet function: relevance to transfusion medicine. Vox Sanq 2005; 88: 153-163.
30. Solheim BG, Flesland O, Seghatchian J, et al. Clinical Implications of red blood cell and platelet storage lessions: an overview. Transf Apher Sci 2004, 31: 185-189.
Labels
Haematology Internal medicine Clinical oncologyArticle was published in
Transfusion and Haematology Today
2011 Issue 2
Most read in this issue
- Case report: secondary thrombocytopenia and disseminated intravascular coagulopathy of the patient with generalized cancer of descending colon
- Clinical relevance of gene mutations in acute myeloid leukemia with normal karyotype
- Detection of clopidogrel resistance by MEA and LTA
- Markers of cell damage of buffy-coat derived platelet concentrates in additive solutions